Insufficient scRNA-seq data for expression of FFAR1 at single-cell level.
Insufficient scRNA-seq data for expression of FFAR1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 100% | 171.50 | 327 / 328 | 59% | 6.60 | 105 / 178 |
| ovary | 98% | 286.54 | 177 / 180 | 11% | 0.35 | 49 / 430 |
| spleen | 92% | 38.83 | 222 / 241 | 0% | 0 | 0 / 0 |
| brain | 85% | 67.19 | 2236 / 2642 | 7% | 0.13 | 47 / 705 |
| lymph node | 0% | 0 | 0 / 0 | 59% | 2.47 | 17 / 29 |
| lung | 44% | 11.85 | 255 / 578 | 1% | 0.01 | 7 / 1155 |
| intestine | 38% | 12.46 | 366 / 966 | 3% | 0.26 | 14 / 527 |
| thymus | 31% | 8.34 | 203 / 653 | 9% | 0.30 | 53 / 605 |
| adrenal gland | 30% | 7.91 | 78 / 258 | 6% | 0.19 | 13 / 230 |
| peripheral blood | 33% | 47.87 | 311 / 929 | 0% | 0 | 0 / 0 |
| uterus | 25% | 9.46 | 42 / 170 | 2% | 0.06 | 8 / 459 |
| prostate | 23% | 5.32 | 57 / 245 | 0% | 0 | 0 / 502 |
| stomach | 22% | 4.41 | 80 / 359 | 1% | 0.02 | 2 / 286 |
| bladder | 19% | 2.19 | 4 / 21 | 0% | 0.01 | 2 / 504 |
| breast | 17% | 3.53 | 77 / 459 | 1% | 0.01 | 10 / 1118 |
| esophagus | 11% | 1.65 | 163 / 1445 | 1% | 0.01 | 1 / 183 |
| adipose | 12% | 1.63 | 141 / 1204 | 0% | 0 | 0 / 0 |
| skin | 3% | 0.44 | 54 / 1809 | 5% | 0.20 | 25 / 472 |
| kidney | 7% | 1.17 | 6 / 89 | 1% | 0.01 | 7 / 901 |
| liver | 3% | 0.36 | 7 / 226 | 0% | 0.01 | 1 / 406 |
| blood vessel | 3% | 0.54 | 39 / 1335 | 0% | 0 | 0 / 0 |
| heart | 2% | 0.23 | 16 / 861 | 0% | 0 | 0 / 0 |
| muscle | 0% | 0.05 | 4 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0030073 | Biological process | insulin secretion |
| GO_0032024 | Biological process | positive regulation of insulin secretion |
| GO_1990806 | Biological process | ligand-gated ion channel signaling pathway |
| GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
| GO_0007204 | Biological process | positive regulation of cytosolic calcium ion concentration |
| GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
| GO_0070542 | Biological process | response to fatty acid |
| GO_0032691 | Biological process | negative regulation of interleukin-1 beta production |
| GO_0042593 | Biological process | glucose homeostasis |
| GO_0099105 | Biological process | ion channel modulating, G protein-coupled receptor signaling pathway |
| GO_0051928 | Biological process | positive regulation of calcium ion transport |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0045125 | Molecular function | bioactive lipid receptor activity |
| GO_0004930 | Molecular function | G protein-coupled receptor activity |
| GO_0008289 | Molecular function | lipid binding |
| Gene name | FFAR1 |
| Protein name | Free fatty acid receptor 1 (G-protein coupled receptor 40) |
| Synonyms | GPCR40 GPR40 |
| Description | FUNCTION: G-protein coupled receptor for medium and long chain saturated and unsaturated fatty acids that plays an important role in glucose homeostasis. Fatty acid binding increases glucose-stimulated insulin secretion, and may also enhance the secretion of glucagon-like peptide 1 (GLP-1). May also play a role in bone homeostasis; receptor signaling activates pathways that inhibit osteoclast differentiation (By similarity). Ligand binding leads to a conformation change that triggers signaling via G-proteins that activate phospholipase C, leading to an increase of the intracellular calcium concentration. Seems to act through a G(q) and G(i)-mediated pathway. Mediates the anti-inflammatory effects of omega-3 polyunsaturated fatty acids (PUFAs) via inhibition of NLRP3 inflammasome activation. . |
| Accessions | Q0IJ71 ENST00000246553.4 O14842 A5Z1T7 |